Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Viatris (VTRS) at Outperform
- Meta Platforms (META) call put ratio 1.7 calls to 1 put with a focus on 11200 contracts of October 16 calls trading at $60
- AstraZeneca extends Young Health Programme with $100m total investment
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
